We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and hi... Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs. Show more
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has determined it is unable to file...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is conducting a process to explore...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Jose Vieira, CEO of...
Dear Shareholders, We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January...
Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated...
Procaps Group (NASDAQ: PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking...
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America PR Newswire BARRANQUILLA, Colombia and MEXICO CITY and MIAMI, Nov. 29...
Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma’s Strategic Marketing and Distribution Footprint Procaps Group (NASDAQ: PROC) (“Procaps”), a leading...
Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO...
Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -0.724637681159 | 2.76 | 3.38 | 2.6 | 5261 | 2.81484394 | CS |
| 4 | 0.04 | 1.48148148148 | 2.7 | 3.38 | 2.53 | 3552 | 2.71114723 | CS |
| 12 | -0.44 | -13.8364779874 | 3.18 | 3.84 | 2.53 | 12823 | 2.98325375 | CS |
| 26 | -0.38 | -12.1794871795 | 3.12 | 4.95 | 2.325 | 30010 | 3.19941278 | CS |
| 52 | -1.5801 | -36.5755422328 | 4.3201 | 4.95 | 1.95 | 19493 | 3.31188315 | CS |
| 156 | -5.67 | -67.4197384067 | 8.41 | 11.98 | 1.95 | 29974 | 6.89042199 | CS |
| 260 | -5.67 | -67.4197384067 | 8.41 | 11.98 | 1.95 | 29974 | 6.89042199 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
